Search

Your search keyword '"Keating, Michael J."' showing total 565 results
Start Over Author "Keating, Michael J." Search Limiters Academic (Peer-Reviewed) Journals
565 results on '"Keating, Michael J."'

4. Topological Structures in the Space of Treatment-Naïve Patients with Chronic Lymphocytic Leukemia.

Author

McGee II, Reginald L., Reed, Jake, Coombes, Caitlin E., Herling, Carmen D., Keating, Michael J., Abruzzo, Lynne V., and Coombes, Kevin R.

Subjects
CHRONIC lymphocytic leukemia, STATISTICAL models, COMPUTER-assisted image analysis (Medicine), RESEARCH funding, CANCER patients, TECHNOLOGY, DIGITAL image processing, GENETIC mutation
Abstract

Simple Summary: Clinical data sets incorporate continuous data like blood pressure or sodium levels, categorical data like cancer grade or stage, and binary data like sex or marital status. Measurements on an individual patient define a point in a high-dimensional space; data from many patients defines a "point cloud". The "shape" of the point cloud influences experimental design by describing patient variability. Topological data analysis (TDA) is a mathematical technique for understanding the shape of point clouds by finding "holes" that correspond to combinations of patient characteristics that are never observed. TDA results are stratified by dimension. Zero-dimensional features define patient subtypes. One-dimensional features ("loops") are analogs of the inside of a circle or a donut hole. Two-dimensional features ("voids") are analogs of the inside of a balloon. Here, we apply TDA to a clinical data set of previously untreated patients with Chronic Lymphocytic Leukemia to find loops and voids. Patients are complex and heterogeneous; clinical data sets are complicated by noise, missing data, and the presence of mixed-type data. Using such data sets requires understanding the high-dimensional "space of patients", composed of all measurements that define all relevant phenotypes. The current state-of-the-art merely defines spatial groupings of patients using cluster analyses. Our goal is to apply topological data analysis (TDA), a new unsupervised technique, to obtain a more complete understanding of patient space. We applied TDA to a space of 266 previously untreated patients with Chronic Lymphocytic Leukemia (CLL), using the "daisy" metric to compute distances between clinical records. We found clear evidence for both loops and voids in the CLL data. To interpret these structures, we developed novel computational and graphical methods. The most persistent loop and the most persistent void can be explained using three dichotomized, prognostically important factors in CLL: IGHV somatic mutation status, beta-2 microglobulin, and Rai stage. In conclusion, patient space turns out to be richer and more complex than current models suggest. TDA could become a powerful tool in a researcher's arsenal for interpreting high-dimensional data by providing novel insights into biological processes and improving our understanding of clinical and biological data sets. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study

Author

Herling, Carmen D, Coombes, Kevin R, Benner, Axel, Bloehdorn, Johannes, Barron, Lynn L, Abrams, Zachary B, Majewski, Tadeusz, Bondaruk, Jolanta E, Bahlo, Jasmin, Fischer, Kirsten, Hallek, Michael, Stilgenbauer, Stephan, Czerniak, Bogdan A, Oakes, Christopher C, Ferrajoli, Alessandra, Keating, Michael J, and Abruzzo, Lynne V

Published
2019
Full Text
View/download PDF

10. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

Author

Burger, Jan A., Sivina, Mariela, Jain, Nitin, Kim, Ekaterina, Kadia, Tapan, Estrov, Zeev, Nogueras-Gonzalez, Graciela M., Huang, Xuelin, Jorgensen, Jeffrey, Li, Jianling, Cheng, Mei, Clow, Fong, Ohanian, Maro, Andreeff, Michael, Mathew, Thomas, Thompson, Philip, Kantarjian, Hagop, O'Brien, Susan, Wierda, William G., Ferrajoli, Alessandra, and Keating, Michael J.

Published
2019
Full Text
View/download PDF

13. Growth dynamics in naturally progressing chronic lymphocytic leukaemia

Author

Gruber, Michaela, Bozic, Ivana, Leshchiner, Ignaty, Livitz, Dimitri, Stevenson, Kristen, Rassenti, Laura, Rosebrock, Daniel, Taylor-Weiner, Amaro, Olive, Oriol, Goyetche, Reaha, Fernandes, Stacey M., Sun, Jing, Stewart, Chip, Wong, Alicia, Cibulskis, Carrie, Zhang, Wandi, Reiter, Johannes G., Gerold, Jeffrey M., Gribben, John G., Rai, Kanti R., Keating, Michael J., Brown, Jennifer R., Neuberg, Donna, Kipps, Thomas J., Nowak, Martin A., Getz, Gad, and Wu, Catherine J.

Published
2019
Full Text
View/download PDF

18. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

Author

O'Brien, Susan, Jones, Jeffrey A, Coutre, Steven E, Mato, Anthony R, Hillmen, Peter, Tam, Constantine, Österborg, Anders, Siddiqi, Tanya, Thirman, Michael J, Furman, Richard R, Ilhan, Osman, Keating, Michael J, Call, Timothy G, Brown, Jennifer R, Stevens-Brogan, Michelle, Li, Yunfeng, Clow, Fong, James, Danelle F, Chu, Alvina D, Hallek, Michael, and Stilgenbauer, Stephan

Published
2016
Full Text
View/download PDF

24. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth

Author

Cramer, Shira L, Saha, Achinto, Liu, Jinyun, Tadi, Surendar, Tiziani, Stefano, Yan, Wupeng, Triplett, Kendra, Lamb, Candice, Alters, Susan E, Rowlinson, Scott, Zhang, Yan Jessie, Keating, Michael J, Huang, Peng, DiGiovanni, John, Georgiou, George, and Stone, Everett

Subjects
Cysteine -- Health aspects, Carcinogenesis -- Genetic aspects -- Risk factors, Reactive oxygen species -- Health aspects, Biological sciences, Health
Abstract

Author(s): Shira L Cramer [1]; Achinto Saha [2]; Jinyun Liu [3]; Surendar Tadi [4]; Stefano Tiziani [4]; Wupeng Yan [5]; Kendra Triplett [1, 5]; Candice Lamb [1, 5]; Susan E [...]

Published
2017
Full Text
View/download PDF

25. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs

Author

Londin, Eric, Loher, Phillipe, Telonis, Aristeidis G., Quann, Kevin, Clark, Peter, Jing, Yi, Hatzimichael, Eleftheria, Kirino, Yohei, Honda, Shozo, Lally, Michelle, Ramratnam, Bharat, Comstock, Clay E. S., Knudsen, Karen E., Gomella, Leonard, Spaeth, George L., Hark, Lisa, Katz, L. Jay, Witkiewicz, Agnieszka, Rostami, Abdolmohamad, Jimenez, Sergio A., Hollingsworth, Michael A., Yeh, Jen Jen, Shaw, Chad A., McKenzie, Steven E., Bray, Paul, Nelson, Peter T., Zupo, Simona, Van Roosbroeck, Katrien, Keating, Michael J., Calin, George A., Yeo, Charles, Jimbo, Masaya, Cozzitorto, Joseph, Brody, Jonathan R., Delgrosso, Kathleen, Mattick, John S., Fortina, Paolo, and Rigoutsos, Isidore

Published
2015

29. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

Author

Burger, Jan A, Keating, Michael J, Wierda, William G, Hartmann, Elena, Hoellenriegel, Julia, Rosin, Nathalie Y, de Weerdt, Iris, Jeyakumar, Ghayathri, Ferrajoli, Alessandra, Cardenas-Turanzas, Marylou, Lerner, Susan, Jorgensen, Jeffrey L, Nogueras-González, Graciela M, Zacharian, Gracy, Huang, Xuelin, Kantarjian, Hagop, Garg, Naveen, Rosenwald, Andreas, and O'Brien, Susan

Published
2014
Full Text
View/download PDF

33. The absolute percent deviation of IGHV mutation rather than a 98% cut‐off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab

Author

Jain, Preetesh, Nogueras González, Graciela M., Kanagal‐Shamanna, Rashmi, Rozovski, Uri, Sarwari, Nawid, Tam, Constantine, Wierda, William G., Thompson, Philip A., Jain, Nitin, Luthra, Rajyalakshmi, Quesada, Andres, Sanchez‐Petitto, Gabriela, Ferrajoli, Alessandra, Burger, Jan, Kantarjian, Hagop, Cortes, Jorge, OʼBrien, Susan, Keating, Michael J., and Estrov, Zeev

Published
2018
Full Text
View/download PDF

39. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.

Author

Boddu, Prajwal C., Senapati, Jayastu, Ravandi‐Kashani, Farhad, Jabbour, Elias J., Jain, Nitin, Ayres, Mary, Chen, Yuling, Keating, Michael J., Kantarjian, Hagop M., Gandhi, Varsha, and Kadia, Tapan M.

Subjects
PHARMACOLOGY, LYMPHOBLASTIC leukemia, CENTRAL nervous system, ACUTE leukemia, PERIPHERAL neuropathy
Abstract

Background: Nelarabine is a purine nucleoside analogue prodrug approved for the treatment of relapsed and refractory T‐cell acute lymphoblastic leukemia (R/R T‐ALL) and lymphoblastic lymphoma (T‐LBL). Although effective in R/R T‐ALL, significant neurotoxicity is dose‐limiting and such neurotoxicity associated with nucleoside analogues can be related to dosing schedule. Methods: The authors conducted a phase 1 study to evaluate the pharmacokinetics and toxicity of nelarabine administered as a continuous infusion (CI) for 5 days (120 hours), rather than the standard, short‐infusion approach. Results: Twenty‐nine patients with R/R T‐ALL/LBL or T‐cell prolymphocytic leukemia (T‐PLL) were treated, with escalating doses of nelarabine from 100 to 800 mg/m2/day × 5 days. The median age of the patients was 39 years (range, 14–77 years). The overall response rate was 31%, including 27% complete remission (CR) or CR with incomplete platelet recovery (CRp). Peripheral neuropathy was observed in 34% of patients, including four ≥grade 3 events related to nelarabine. Notably, there was no nelarabine‐related central neurotoxicity on study. The maximum tolerated dose was not reached. Pharmacokinetic data suggested no relationship between dose of nelarabine and accumulation of active intracellular ara‐GTP metabolite. Higher intracellular ara‐GTP concentrations were statistically associated with a favorable clinical response. Conclusion: Preliminary evaluation of continuous infusion schedule of nelarabine suggests that the safety profile is acceptable for this patient population, with clinical activity observed even at low doses and could broaden the use of nelarabine both as single agent and in combinations by potentially mitigating the risk of central nervous system toxicities. Nelarabine administered as continuous infusion is safe and has significant clinical activity in patients with T‐cell leukemia. The continuous infusion schedule of nelarabine was not associated with central neurotoxicity in this study. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

Author

Takahashi, Koichi, Sivina, Mariela, Hoellenriegel, Julia, Oki, Yasuhiro, Hagemeister, Fredrick B., Fayad, Luis, Romaguera, Jorge E., Fowler, Nathan, Fanale, Michelle A., Kwak, Larry W., Samaniego, Felipe, Neelapu, Sattva, Xiao, Lianchun, Huang, Xuelin, Kantarjian, Hagop, Keating, Michael J., Wierda, William, Fu, Kai, Chan, Wing C., Vose, Julie M., OʼBrien, Susan, Davis, Richard E., and Burger, Jan A.

Published
2015
Full Text
View/download PDF

48. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients

Author

Stephens, Deborah M., Ruppert, Amy S., Weirda, William G., Jones, Jeffrey A., Woyach, Jennifer A., Maddocks, Kami, Jaglowski, Samantha M., Andritsos, Leslie A., Flynn, Joseph M., Grever, Michael R., Lozanski, Gerard, Tam, Constantine, OʼBrien, Susan, Keating, Michael J., Muthusamy, Natarajan, Abruzzo, Lynne V., Heerema, Nyla A., and Byrd, John C.

Published
2015
Full Text
View/download PDF

49. The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy – the MD Anderson Cancer Center experience

Author

Thompson, Philip A., Rozovski, Uri, Keating, Michael J., Stingo, Francesco, Smith, Susan C., Wierda, William G., Falchi, Lorenzo, OʼBrien, Susan M., Estrov, Zeev, Burger, Jan A., and Ferrajoli, Alessandra

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results